Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALaDIN
NCT06884280Phase 3Recruiting
- Sponsor
- Hull University Teaching Hospitals
- Start
- Nov 2025
- Primary completion
- Oct 2027
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in anemia and iron deficiency anemia (IDA) (3 arms), sponsored by Hull University Teaching Hospitals. Primary endpoints: Eligibility to consent rate at 12 months, Recruitment rate at 12 months and 6 more. Started Nov 2025; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
anemiairon deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06884280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06884280.